MedinCell S.A. (MDCLF)
USD 6.98
(0.0%)
USD 6.98
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 30.13 Million EUR | -11.33% |
| 2023 | 33.98 Million EUR | 21.81% |
| 2022 | 27.9 Million EUR | 24.89% |
| 2021 | 22.34 Million EUR | 0.98% |
| 2020 | 22.12 Million EUR | 38.74% |
| 2019 | 15.94 Million EUR | 17.97% |
| 2018 | 13.52 Million EUR | 30.14% |
| 2017 | 10.38 Million EUR | 33.0% |
| 2016 | 7.81 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 16.28 Million EUR | 131.05% |
| 2024 Q1 | 7.04 Million EUR | -59.76% |
| 2024 Q3 | 9.36 Million EUR | -42.47% |
| 2024 FY | 31.19 Million EUR | -8.23% |
| 2024 Q4 | 7.88 Million EUR | -15.88% |
| 2023 Q2 | 18.54 Million EUR | 88.89% |
| 2023 Q4 | 17.51 Million EUR | 58.24% |
| 2023 Q1 | 9.81 Million EUR | -38.88% |
| 2023 FY | 33.98 Million EUR | 21.81% |
| 2023 Q3 | 11.06 Million EUR | -40.32% |
| 2022 Q1 | 7.51 Million EUR | -51.36% |
| 2022 FY | 27.9 Million EUR | 24.89% |
| 2022 Q4 | 16.06 Million EUR | 96.83% |
| 2022 Q3 | 8.16 Million EUR | -44.3% |
| 2022 Q2 | 14.65 Million EUR | 95.11% |
| 2021 Q1 | 5.72 Million EUR | -54.26% |
| 2021 Q4 | 15.44 Million EUR | 153.65% |
| 2021 Q3 | 6.08 Million EUR | -41.72% |
| 2021 Q2 | 10.44 Million EUR | 82.4% |
| 2021 FY | 22.34 Million EUR | 0.98% |
| 2020 FY | 22.12 Million EUR | 38.74% |
| 2020 Q2 | 11.44 Million EUR | 91.79% |
| 2020 Q3 | 6.72 Million EUR | -41.2% |
| 2020 Q4 | 12.52 Million EUR | 86.05% |
| 2020 Q1 | 5.96 Million EUR | 8.14% |
| 2019 Q3 | 5.51 Million EUR | 4.05% |
| 2019 FY | 15.94 Million EUR | 17.97% |
| 2019 Q2 | 5.3 Million EUR | 0.0% |
| 2019 Q1 | 5.3 Million EUR | 19.18% |
| 2019 Q4 | 5.51 Million EUR | 0.0% |
| 2018 Q3 | 4.44 Million EUR | 34.69% |
| 2018 Q4 | 4.44 Million EUR | 0.0% |
| 2018 FY | 13.52 Million EUR | 30.14% |
| 2018 Q1 | 3.3 Million EUR | 0.0% |
| 2018 Q2 | 3.3 Million EUR | 0.0% |
| 2017 FY | 10.38 Million EUR | 33.0% |
| 2016 FY | 7.81 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 65.274% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -512.801% |
| SQZ Biotechnologies Company | 85.61 Million USD | 64.801% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -1.976% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 19.108% |
| Mesoblast Limited | 5.9 Million USD | -410.624% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1906.593% |
| Genus plc | 147.7 Million USD | 79.596% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -243.276% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2146.44% |
| Marizyme, Inc. | 19.23 Million USD | -56.639% |
| ContraFect Corporation | 56.88 Million USD | 47.025% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -261.398% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -583.585% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1938.002% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -933.422% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -980.041% |
| MultiCell Technologies, Inc. | 567.42 USD | -5311133.302% |
| Accustem Sciences Inc. | 3.74 Million USD | -704.422% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 64.935% |
| EV Biologics, Inc. | 531.96 Thousand USD | -5565.254% |
| Q BioMed Inc. | 3.43 Million USD | -776.935% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -21.938% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -7636.045% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1046.974% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2931.336% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 86.635% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -348.6% |
| Skye Bioscience, Inc. | 13.54 Million USD | -122.454% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1371.027% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 120648.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -497.714% |
| IMV Inc. | 37.7 Million USD | 20.081% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -88.236% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1542.258% |
| GB Sciences, Inc. | 1.42 Million USD | -2021.563% |
| Alpha Cognition Inc. | 9.7 Million USD | -210.511% |
| HST Global, Inc. | 140.9 Thousand USD | -21287.866% |
| CSL Limited | 3.44 Billion USD | 99.126% |
| Halberd Corporation | 74.84 Thousand USD | -40167.497% |
| Enzolytics Inc. | 2.17 Million USD | -1282.744% |
| Resverlogix Corp. | 12.71 Million USD | -137.075% |
| Affymax, Inc. | 39.38 Million USD | 23.483% |
| SYBLEU INC | 160.87 Thousand USD | -18633.061% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -725.511% |
| argenx SE | 1.53 Billion USD | 98.035% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 47.533% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2786.686% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1808.184% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -785.086% |
| AVAX Technologies, Inc. | 7.31 Million USD | -312.256% |
| Zenith Capital Corp. | 8.94 Million USD | -236.99% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.349% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -172892.366% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1127.418% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -17471.673% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 69.66% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1612.643% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1428.219% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1516.471% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -177.326% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1468.895% |
| BioStem Technologies, Inc. | 22.97 Million USD | -31.174% |
| ONE Bio Corp. | 6.44 Million USD | -367.683% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -16505.78% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2156.725% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2579.059% |
| Agentix Corp. | 1.37 Million USD | -2096.965% |
| LadRx Corporation | 3.81 Million USD | -690.626% |
| Cell Source, Inc. | 4.32 Million USD | -596.754% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -7153.556% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3163.311% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3163.311% |
| NovAccess Global Inc. | 2.46 Million USD | -1121.724% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1153.132% |
| Itoco Inc. | 919.14 Thousand USD | -3178.815% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -611.044% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2593.208% |
| Kadimastem Ltd | 2.41 Million USD | -1150.44% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -11414.714% |
| CytoDyn Inc. | 18.05 Million USD | -66.89% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -119638.567% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5334.536% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -13593.781% |
| Qrons Inc. | 643.67 Thousand USD | -4582.007% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2022.635% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1251.508% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4438.705% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1559.234% |
| International Stem Cell Corporation | 5.27 Million USD | -471.751% |
| Bioxytran, Inc. | 3.82 Million USD | -688.896% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -57148.965% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -148044.325% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 16.9% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1762.608% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3995.619% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -868.724% |
| Neutra Corp. | 243.82 Thousand USD | -12260.297% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -72.636% |
| PureTech Health plc | 144.59 Million USD | 79.158% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -47.082% |
| IXICO plc | 4.7 Million USD | -540.259% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -242.583% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 74.406% |
| CSL Limited | 3.89 Billion USD | 99.226% |
| Cellectis S.A. | 97.32 Million USD | 69.033% |